Effect of Colchicine on Arterial Stiffness in Patients With Hypertension: The COlchicine HypERtENsion Trial (COHERENT)

AIM: This trial investigated whether colchicine, an anti-inflammatory treatment, affects cardiovascular structure and function, assessed by arterial stiffness, blood pressure and biochemistry, compared with placebo. METHODS: COHERENT was a randomized, double-blind, placebo-controlled trial of the effects of colchicine on arterial stiffness in adults with pharmacologically treated hypertension without cardiovascular disease. Eligible patients were randomized 1:1 to colchicine 0.5mg daily or placebo for six months. Assessment of arterial stiffness, echocardiography, and biomarker measurement were performed at baseline and six months. The primary endpoint was change in carotid-femoral pulse wave velocity (cfPWV). Secondary endpoints included change in blood pressure (BP), left ventricular mass index, as well as change in cardiac and inflammatory biomarkers. RESULTS: Of 183 screened, 150 were randomized (75 per group). Mean age was 64.5 (±8.0) years, 53 (35.3%) were female, and mean systolic blood pressure was 137.6 (±15.6) mmHg. At six months, cfPWV did not differ between groups (between-group difference in ΔcfPWV -0.1m/s, 95% CI: -0.5 to 0.3m/s, p=0.53). Office systolic BP decreased significantly more in the placebo group than in the colchicine group (between-group difference in Δoffice systolic BP 5.7 mmHg, 95% CI: 1.0 to 10.5 mmHg, p=0.018. hsCRP decreased significantly in the colchicine group compared with the placebo group (between-group difference in % change in hsCRP -39.8%, 95% CI: -59.1 to -11.4%, p=0.010). Left ventricular mass index or cardiac biomarkers did not differ between groups. CONCLUSIONS: Six months of colchicine did not affect arterial stiffness in pharmacologically treated hypertension without cardiovascular disease. Colchicine significantly decreased hsCRP.

Authors

Institutions

Publication Details

Journal
European Journal of Preventive Cardiology
Published
2026-10-15
DOI
https://doi.org/10.1093/eurjpc/zwag527
Primary Topic
Cardiovascular Health and Disease Prevention
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of Colchicine on Arterial Stiffness in Patients With Hypertension: The COlchicine HypERtENsion Trial (COHERENT)

Nino Emanuel Landler, Katja Vu Bartholdy, Caroline Espersen, Ahmad Sajadieh et al.
European Journal of Preventive Cardiology
Cardiovascular Health and Disease Prevention
article

Effect of Colchicine on Arterial Stiffness in Patients With Hypertension: The COlchicine HypERtENsion Trial (COHERENT)

Nino Emanuel Landler, Katja Vu Bartholdy, Caroline Espersen, Ahmad Sajadieh, Marie Frimodt‐Møller, Lise Witten Davodian, Camilla Ikast Ottosen, Anne Marie Reimer Jensen, Kristoffer Grundtvig Skaarup, Güldas Köse, Adam Cadovius Femerling Langhoff, Filip Soeskov Davidovski, Lisa Steen Duus, Anne Bjerg Nielsen, Daniel Modin, Maria Dons, Niklas Dyrby Johansen, Tor Biering‐Sørensen, Thomas A. Jepps, Jakob Øystein Simonsen, Marat Yafasov, Julie Borchsenius, Frederik Holme Fussing, Tina Ken Schramm, Mats Christian Højbjerg Lassen, Morten Sengeløv
article en

Abstract

AIM: This trial investigated whether colchicine, an anti-inflammatory treatment, affects cardiovascular structure and function, assessed by arterial stiffness, blood pressure and biochemistry, compared with placebo. METHODS: COHERENT was a randomized, double-blind, placebo-controlled trial of the effects of colchicine on arterial stiffness in adults with pharmacologically treated hypertension without cardiovascular disease. Eligible patients were randomized 1:1 to colchicine 0.5mg daily or placebo for six months. Assessment of arterial stiffness, echocardiography, and biomarker measurement were performed at baseline and six months. The primary endpoint was change in carotid-femoral pulse wave velocity (cfPWV). Secondary endpoints included change in blood pressure (BP), left ventricular mass index, as well as change in cardiac and inflammatory biomarkers. RESULTS: Of 183 screened, 150 were randomized (75 per group). Mean age was 64.5 (±8.0) years, 53 (35.3%) were female, and mean systolic blood pressure was 137.6 (±15.6) mmHg. At six months, cfPWV did not differ between groups (between-group difference in ΔcfPWV -0.1m/s, 95% CI: -0.5 to 0.3m/s, p=0.53). Office systolic BP decreased significantly more in the placebo group than in the colchicine group (between-group difference in Δoffice systolic BP 5.7 mmHg, 95% CI: 1.0 to 10.5 mmHg, p=0.018. hsCRP decreased significantly in the colchicine group compared with the placebo group (between-group difference in % change in hsCRP -39.8%, 95% CI: -59.1 to -11.4%, p=0.010). Left ventricular mass index or cardiac biomarkers did not differ between groups. CONCLUSIONS: Six months of colchicine did not affect arterial stiffness in pharmacologically treated hypertension without cardiovascular disease. Colchicine significantly decreased hsCRP.

European Journal of Preventive Cardiology
University of Copenhagen (DK), Bispebjerg Hospital (DK), Copenhagen University Hospital (DK), Gentofte Hospital (DK), Rigshospitalet (DK), Steno Diabetes Center Copenhagen (DK)
Openalex Percentile: Top 12%
Cardiovascular Health and Disease Prevention
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.